{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:52:47Z","timestamp":1793137967072,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T00:00:00Z","timestamp":1477872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jim.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T19:30:28Z","timestamp":1477337428000},"page":"41-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome"],"prefix":"10.1016","volume":"440","author":[{"given":"Andrew C.","family":"Melton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Russell K.","family":"Soon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky","family":"Schweighardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Zoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Jesaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2016.10.006_bb0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.jim.2016.10.006_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymgme.2013.08.002","article-title":"The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase","volume":"110","author":"Barbier","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2016.10.006_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"Benichou","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2016.10.006_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1750-1172-8-51","article-title":"Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase","volume":"8","author":"Brands","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jim.2016.10.006_bb0025","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jim.2016.10.006_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.jim.2016.10.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012194","article-title":"Enzyme replacement in a human model of Mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice","volume":"5","author":"Dvorak-Ewell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jim.2016.10.006_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2006.12.004","article-title":"Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics","volume":"321","author":"Gupta","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2016.10.006_bb0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","article-title":"The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects","volume":"109","author":"Harmatz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2016.10.006_bb0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.jim.2016.10.006_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","article-title":"Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA","volume":"110","author":"Hendriksz","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2016.10.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009354.pub2","article-title":"Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I","volume":"9","author":"Jameson","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jim.2016.10.006_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2016.10.006_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.11.017","article-title":"Long-term immunogenicity of elosulfase alfa in the treatment of Morquio A syndrome: results from MOR-005, a phase III extension study","author":"Long","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jim.2016.10.006_bb0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/1352458509105384","article-title":"High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study","volume":"15","author":"Millonig","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jim.2016.10.006_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2016.10.006_bb0090","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)00140-9","article-title":"Mannose 6-phosphate\/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis","volume":"103","author":"Motyka","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jim.2016.10.006_bb0095","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/eji.1830221135","article-title":"Evidence for an association between the T cell receptor\/CD3 antigen complex and the CD5 antigen in human T lymphocytes","volume":"22","author":"Osman","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jim.2016.10.006_bb0100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","article-title":"Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome","volume":"53","author":"Qi","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jim.2016.10.006_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0022-1759(83)90340-X","article-title":"Differentiation between attached and ingested immune complexes by a fluorescence quenching cytofluorometric assay","volume":"60","author":"Sahlin","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2016.10.006_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jim.2016.10.006_bb0120","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jim.2016.10.006_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2474-14-S2-P18","article-title":"Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age","volume":"14","author":"van Gelder","year":"2013","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.jim.2016.10.006_bb0130","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1074\/jbc.M708723200","article-title":"Cell surface-expressed cation-independent mannose 6-phosphate receptor (CD222) binds enzymatically active heparanase independently of mannose 6-phosphate to promote extracellular matrix degradation","volume":"283","author":"Wood","year":"2008","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591630285X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591630285X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T08:54:00Z","timestamp":1536310440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002217591630285X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":24,"alternative-id":["S002217591630285X"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2016.10.006","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibodies that neutralize cellular uptake of elosulfase alfa are not associated with reduced efficacy or pharmacodynamic effect in individuals with Morquio A syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}